Martin R. Weber

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Clinical Oncology · 2010 · 448 citations

Medicine, Oncology, Pharmacology +17

Adaptation of Energy Metabolism in Breast Cancer Brain Metastases

Emily I. Chen, Johannes A. Hewel, Joseph S. Krueger et al. · Cancer Research · 2007 · 355 citations

Medicine, Cancer Biology, Oncology +17

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Shirin Khambata‐Ford, Christopher Harbison, Lowell L. Hart et al. · Journal of Clinical Oncology · 2010 · 268 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

Charles Butts, David Bodkin, Edward L. Middleman et al. · Journal of Clinical Oncology · 2007 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Thoracic Oncology · 2007 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17